Global TCR-Based Antibody Market
Global TCR-Based Antibody Market

TCR-Based Antibody Comprehensive Study by Type (NY-ESO-1, P53, WT-1, EBv), Application (Hospitals, Specialized clinics, Pharma and Biotech research laboratories., Gene therapy Centers), By Indications (Bladder cancer, Multiple myeloma)

TCR-Based Antibody Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Aug 2021 Edition 210 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global TCR-Based Antibody Market Overview:
The TCR Based Antibody is an antibody that is used when there is a need to kill the CD-19 positive cancer cells. Due to an increase in many diseases like Leukemia, Lymphoma, etc., in which normal antibodies don’t work. Thus, in such a situation the TCR-based antibody is advised by a doctor which is effectively impacting diseases. These antibodies are target explicitly and tie and kill the objective thus the transformation of the altered antibodies is expanding because of amazing outcomes. ImmTAC molecules are a novel class of T cell redirecting specific biologics that exploit TCR-based targeting of tumor cells; providing potent and highly specific access to the vast landscape of intracellular targets.

Growth Drivers
  • Rise in the adaption of the TCR-bases antibodies to create a positive impact
  • The prevalence of lymphoma through TCR based antibodies are increases across the countries

Roadblocks
  • High cost of TCR based antibody treatment for different diseases
  • Stringent rules and regulations of government regarding utilization TCR bases antibody

Opportunities
  • Development of infrastructure regarding pharmaceuticals in emerging countries
  • Development of standard rules and regulations regarding this treatment all across the globe

Challenges
  • Development of cost-efficient TCR based antibody treatment
  • Increase in demand for advanced medical and treatment procedures in emerging countries


Competitive Landscape:
This industry is fragmented by market-leading players, and those are strongly focusing on developing new methodologies by collaborating with the other company and try to get excellence in developing adoptive cell therapies. With the increase in market opportunities, the organizations are making mergers and acquisitions and availing competitive advantages.
Some of the key players profiled in the report are Immunocore (United Kingdom), Kuur Therapeutics (United States), Lion TCR (Singapore), Adaptimmune Therapeutics (United Kingdom), Celgene (United States), Kite Pharma (A Gilead Sciences Company) (United States), Takara Bio (Japan), Ziopharm Oncology (United States), GlaxoSmithKline (United Kingdom) and Merck (Germany). Additionally, following companies can also be profiled that are part of our coverage like Juno Theraprutics (United States), H3 Biomedicine (United States), Immatics (Germany), Kite Pharma (United States) and Adaptive Biotechnologies (United States). Analyst at AMA Research see United States Players to retain maximum share of Global TCR-Based Antibody market by 2026. Considering Market by By Indications, the sub-segment i.e. Bladder cancer will boost the TCR-Based Antibody market.

Latest Market Insights:
On 4 May 2021, Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it has acquired Kuur Therapeutics, Inc., the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies. Kuur’s innovative technology, combined with the TCR program, could propel us into a leadership position in cell therapy. This platform also has the potential to provide synergies with other assets in pipeline.

On 28 August 2019, Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced that Immatics and Celgene Corporation, a Bristol-Myers Squibb Company, have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers. This alliance leverages Immatics’ excellence in developing adoptive cell therapies (ACT) and complements our proprietary clinical pipeline of ACT products and our strong portfolio of Bispecific products.

The food and Drug Administration (FDA) is the regulatory authority in the United States is involved in the formulation of different rules and regulations with respect to the utilization of TCR-based antibody treatment. Also, FDA is the authority that provides guidelines regarding research and development in TCR-based antibody treatment.

What Can be Explored with the TCR-Based Antibody Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global TCR-Based Antibody Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in TCR-Based Antibody
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global TCR-Based Antibody market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in TCR-Based Antibody market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceuticals Companies, Cancer Hospitals, Government Regulatory Bodies, Private Research Institutions, Industrial Associations and Government Research Institutions.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global TCR-Based Antibody Market?
The TCR-Based Antibody market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in TCR-Based Antibody Market?
Top performing companies in the Global TCR-Based Antibody market are Immunocore (United Kingdom), Kuur Therapeutics (United States), Lion TCR (Singapore), Adaptimmune Therapeutics (United Kingdom), Celgene (United States), Kite Pharma (A Gilead Sciences Company) (United States), Takara Bio (Japan), Ziopharm Oncology (United States), GlaxoSmithKline (United Kingdom) and Merck (Germany), to name a few.

3. What trending factors would impact TCR-Based Antibody Market growth most?
"Continuous development and finding of more T-Cell therapies " is seen as one of major influencing trends for TCR-Based Antibody Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Type
  • NY-ESO-1
  • p53
  • WT-1
  • EBv
By Application
  • Hospitals
  • Specialized clinics
  • Pharma and Biotech research laboratories.
  • Gene therapy Centers
By By Indications
  • Bladder cancer
  • Multiple myeloma

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Rise in the adaption of the TCR-bases antibodies to create a positive impact
        • 3.2.2. The prevalence of lymphoma through TCR based antibodies are increases across the countries
      • 3.3. Market Challenges
        • 3.3.1. Development of cost-efficient TCR based antibody treatment
        • 3.3.2. Increase in demand for advanced medical and treatment procedures in emerging countries
      • 3.4. Market Trends
        • 3.4.1. Continuous development and finding of more T-Cell therapies
        • 3.4.2. Increase in Research for expanding product offering in relation to pharm and biotechnology
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global TCR-Based Antibody, by Type, Application and By Indications (value and price ) (2015-2020)
      • 5.1. Introduction
      • 5.2. Global TCR-Based Antibody (Value)
        • 5.2.1. Global TCR-Based Antibody by: Type (Value)
          • 5.2.1.1. NY-ESO-1
          • 5.2.1.2. P53
          • 5.2.1.3. WT-1
          • 5.2.1.4. EBv
        • 5.2.2. Global TCR-Based Antibody by: Application (Value)
          • 5.2.2.1. Hospitals
          • 5.2.2.2. Specialized clinics
          • 5.2.2.3. Pharma and Biotech research laboratories.
          • 5.2.2.4. Gene therapy Centers
        • 5.2.3. Global TCR-Based Antibody by: By Indications (Value)
          • 5.2.3.1. Bladder cancer
          • 5.2.3.2. Multiple myeloma
      • 5.3. Global TCR-Based Antibody (Price)
        • 5.3.1. Global TCR-Based Antibody by: Type (Price)
    • 6. TCR-Based Antibody: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2020)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. Immunocore (United Kingdom)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. Kuur Therapeutics (United States)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. Lion TCR (Singapore)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Adaptimmune Therapeutics (United Kingdom)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Celgene (United States)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. Kite Pharma (A Gilead Sciences Company) (United States)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Takara Bio (Japan)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Ziopharm Oncology (United States)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. GlaxoSmithKline (United Kingdom)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. Merck (Germany)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
    • 7. Global TCR-Based Antibody Sale, by Type, Application and By Indications (value and price ) (2021-2026)
      • 7.1. Introduction
      • 7.2. Global TCR-Based Antibody (Value)
        • 7.2.1. Global TCR-Based Antibody by: Type (Value)
          • 7.2.1.1. NY-ESO-1
          • 7.2.1.2. P53
          • 7.2.1.3. WT-1
          • 7.2.1.4. EBv
        • 7.2.2. Global TCR-Based Antibody by: Application (Value)
          • 7.2.2.1. Hospitals
          • 7.2.2.2. Specialized clinics
          • 7.2.2.3. Pharma and Biotech research laboratories.
          • 7.2.2.4. Gene therapy Centers
        • 7.2.3. Global TCR-Based Antibody by: By Indications (Value)
          • 7.2.3.1. Bladder cancer
          • 7.2.3.2. Multiple myeloma
      • 7.3. Global TCR-Based Antibody (Price)
        • 7.3.1. Global TCR-Based Antibody by: Type (Price)
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. TCR-Based Antibody: by Type(USD Million)
    • Table 2. TCR-Based Antibody: by Application(USD Million)
    • Table 3. TCR-Based Antibody: by By Indications(USD Million)
    • Table 4. TCR-Based Antibody: by Type(USD/Units)
    • Table 5. Company Basic Information, Sales Area and Its Competitors
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. TCR-Based Antibody: by Type(USD Million)
    • Table 16. TCR-Based Antibody: by Application(USD Million)
    • Table 17. TCR-Based Antibody: by By Indications(USD Million)
    • Table 18. TCR-Based Antibody: by Type(USD/Units)
    • Table 19. Research Programs/Design for This Report
    • Table 20. Key Data Information from Secondary Sources
    • Table 21. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global TCR-Based Antibody: by Type USD Million (2015-2020)
    • Figure 5. Global TCR-Based Antibody: by Application USD Million (2015-2020)
    • Figure 6. Global TCR-Based Antibody: by By Indications USD Million (2015-2020)
    • Figure 7. Global TCR-Based Antibody: by Type USD/Units (2015-2020)
    • Figure 8. Global TCR-Based Antibody share by Players 2020 (%)
    • Figure 9. Global TCR-Based Antibody share by Players (Top 3) 2020(%)
    • Figure 10. Global TCR-Based Antibody share by Players (Top 5) 2020(%)
    • Figure 11. BCG Matrix for key Companies
    • Figure 12. Immunocore (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 13. Immunocore (United Kingdom) Revenue: by Geography 2020
    • Figure 14. Kuur Therapeutics (United States) Revenue, Net Income and Gross profit
    • Figure 15. Kuur Therapeutics (United States) Revenue: by Geography 2020
    • Figure 16. Lion TCR (Singapore) Revenue, Net Income and Gross profit
    • Figure 17. Lion TCR (Singapore) Revenue: by Geography 2020
    • Figure 18. Adaptimmune Therapeutics (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 19. Adaptimmune Therapeutics (United Kingdom) Revenue: by Geography 2020
    • Figure 20. Celgene (United States) Revenue, Net Income and Gross profit
    • Figure 21. Celgene (United States) Revenue: by Geography 2020
    • Figure 22. Kite Pharma (A Gilead Sciences Company) (United States) Revenue, Net Income and Gross profit
    • Figure 23. Kite Pharma (A Gilead Sciences Company) (United States) Revenue: by Geography 2020
    • Figure 24. Takara Bio (Japan) Revenue, Net Income and Gross profit
    • Figure 25. Takara Bio (Japan) Revenue: by Geography 2020
    • Figure 26. Ziopharm Oncology (United States) Revenue, Net Income and Gross profit
    • Figure 27. Ziopharm Oncology (United States) Revenue: by Geography 2020
    • Figure 28. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 29. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
    • Figure 30. Merck (Germany) Revenue, Net Income and Gross profit
    • Figure 31. Merck (Germany) Revenue: by Geography 2020
    • Figure 32. Global TCR-Based Antibody: by Type USD Million (2021-2026)
    • Figure 33. Global TCR-Based Antibody: by Application USD Million (2021-2026)
    • Figure 34. Global TCR-Based Antibody: by By Indications USD Million (2021-2026)
    • Figure 35. Global TCR-Based Antibody: by Type USD/Units (2021-2026)
    Some of the key companies/manufacturers profiled in the report
    • Immunocore (United Kingdom)
    • Kuur Therapeutics (United States)
    • Lion TCR (Singapore)
    • Adaptimmune Therapeutics (United Kingdom)
    • Celgene (United States)
    • Kite Pharma (A Gilead Sciences Company) (United States)
    • Takara Bio (Japan)
    • Ziopharm Oncology (United States)
    • GlaxoSmithKline (United Kingdom)
    • Merck (Germany)
    Additional players considered in the study are as follows:
    Juno Theraprutics (United States) , H3 Biomedicine (United States) , Immatics (Germany) , Kite Pharma (United States) , Adaptive Biotechnologies (United States)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation